SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Idexx Laboratories Inc/DE – ‘10-Q’ for 9/30/19 – ‘EX-32.1’

On:  Thursday, 10/31/19, at 11:59am ET   ·   For:  9/30/19   ·   Accession #:  874716-19-36   ·   File #:  0-19271

Previous ‘10-Q’:  ‘10-Q’ on 8/1/19 for 6/30/19   ·   Next:  ‘10-Q’ on 4/30/20 for 3/31/20   ·   Latest:  ‘10-Q’ on 11/1/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

10/31/19  Idexx Laboratories Inc/DE         10-Q        9/30/19   96:10M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.59M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     34K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     34K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     29K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     29K 
92: R1          Cover Page                                          HTML     80K 
37: R2          Condensed Consolidated Balance Sheets               HTML    141K 
25: R3          Condensed Consolidated Balance Sheets               HTML     43K 
                (Parenthetical)                                                  
61: R4          Condensed Consolidated Statements of Income         HTML     99K 
91: R5          Condensed Consolidated Statements of Comprehensive  HTML     68K 
                Income                                                           
36: R6          Condensed Consolidated Statements of Comprehensive  HTML     37K 
                Income (Parenthetical)                                           
24: R7          Condensed Consolidated Statements of Stockholders'  HTML    103K 
                Equity (Deficit)                                                 
59: R8          Condensed Consolidated Statements of Stockholders'  HTML     30K 
                Equity (Deficit) (Parenthetical)                                 
94: R9          Condensed Consolidated Statements of Cash Flows     HTML    118K 
18: R10         Basis of Presentation and Principles of             HTML     34K 
                Consolidation                                                    
47: R11         Accounting Policies                                 HTML     71K 
82: R12         Revenue Recognition                                 HTML    149K 
71: R13         Acquisitions                                        HTML     31K 
19: R14         Share-Based Compensation                            HTML     43K 
48: R15         Inventories                                         HTML     37K 
84: R16         Property and Equipment, Net                         HTML     29K 
72: R17         Leases                                              HTML     50K 
17: R18         Other Current and Long-Term Assets                  HTML     55K 
49: R19         Accrued Liabilities                                 HTML     47K 
85: R20         Debt                                                HTML     31K 
53: R21         Repurchases Of Common Stock                         HTML     67K 
22: R22         Income Taxes                                        HTML     31K 
32: R23         Accumulated Other Comprehensive Income              HTML    103K 
86: R24         Earnings Per Share                                  HTML     58K 
54: R25         Commitments, Contingencies and Guarantees           HTML     32K 
23: R26         Segment Reporting                                   HTML    196K 
33: R27         Fair Value Measurements                             HTML    111K 
87: R28         Hedging Instruments                                 HTML    114K 
52: R29         Accounting Policies (Policies)                      HTML    107K 
69: R30         Accounting Policies (Tables)                        HTML     65K 
81: R31         Revenue Recognition (Tables)                        HTML     90K 
51: R32         Share-Based Compensation (Tables)                   HTML     39K 
21: R33         Inventories (Tables)                                HTML     38K 
68: R34         Leases (Tables)                                     HTML     46K 
80: R35         Other Current and Long-Term Assets (Tables)         HTML     57K 
50: R36         Accrued Liabilities (Tables)                        HTML     48K 
20: R37         Repurchases of Common Stock (Tables)                HTML     66K 
70: R38         Accumulated Other Comprehensive Income (Tables)     HTML    105K 
79: R39         Earnings Per Share (Tables)                         HTML     59K 
60: R40         Segment Reporting (Tables)                          HTML    194K 
96: R41         Fair Value Measurements (Tables)                    HTML    100K 
35: R42         Hedging Instruments (Tables)                        HTML     99K 
27: R43         Accounting Policies (Details)                       HTML     71K 
58: R44         Revenue Recognition (General Narrative) (Details)   HTML     31K 
95: R45         Revenue Recognition (Lease Revenue) (Details)       HTML     28K 
34: R46         Revenue Recognition (Extended Warranties and        HTML     43K 
                Post-Contract Support) (Details)                                 
26: R47         Revenue Recognition (SaaS Subscriptions) (Details)  HTML     29K 
62: R48         Revenue Recognition (Up-Front Customer Loyalty      HTML     37K 
                Programs) (Details)                                              
90: R49         Revenue Recognition (Volume Commitment Programs)    HTML     33K 
                (Details)                                                        
75: R50         Revenue Recognition (Instrument Rebate Programs)    HTML     33K 
                (Details)                                                        
66: R51         Revenue Recognition (Reagent Rental Programs)       HTML     38K 
                (Details)                                                        
11: R52         Revenue Recognition (Disaggregation of Revenue by   HTML     56K 
                Major Product and Service Categories) (Details)                  
41: R53         Revenue Recognition (Disaggregation of Revenue by   HTML     41K 
                Principal Geographic Area, Based on Customers'                   
                Domiciles) (Details)                                             
76: R54         Revenue Recognition (Costs to Obtain a Contract)    HTML     41K 
                (Details)                                                        
67: R55         Revenue Recognition (Remaining Performance          HTML     70K 
                Obligation) (Details)                                            
12: R56         Acquisitions (Details)                              HTML     52K 
42: R57         Share-Based Compensation (Narrative) (Details)      HTML     37K 
77: R58         Share-Based Compensation (Assumptions Used)         HTML     38K 
                (Details)                                                        
65: R59         Inventories (Details)                               HTML     38K 
29: R60         Property and Equipment, Net (Details)               HTML     30K 
38: R61         Leases (Maturities of Operating Lease Liabilities)  HTML     56K 
                (Details)                                                        
88: R62         Leases (Supplemental Cash Flow Information)         HTML     30K 
                (Details)                                                        
56: R63         Leases (Narrative) (Details)                        HTML     27K 
30: R64         Leases (Previous Lease Accounting Minimum Annual    HTML     44K 
                Rental Payments) (Details)                                       
39: R65         Other Current and Long-Term Assets (Schedule Of     HTML     44K 
                Other Current Assets) (Details)                                  
89: R66         Other Current and Long-Term Assets (Schedule Of     HTML     46K 
                Other Long-term Assets) (Details)                                
57: R67         Accrued Liabilities (Schedule Of Accrued            HTML     43K 
                Liabilities) (Details)                                           
28: R68         Accrued Liabilities (Schedule Of Other Long-term    HTML     34K 
                Liabilities) (Details)                                           
40: R69         Debt (Details)                                      HTML     44K 
45: R70         Repurchases of Common Stock (Details)               HTML     47K 
14: R71         Income Taxes (Details)                              HTML     29K 
64: R72         Accumulated Other Comprehensive Income (Schedule    HTML     53K 
                Of AOCI) (Details)                                               
74: R73         Accumulated Other Comprehensive Income (Schedule    HTML     45K 
                of Reclassifications out of AOCI) (Details)                      
44: R74         Earnings Per Share (Schedule Of Reconciliation Of   HTML     38K 
                Shares Outstanding For Basic And Diluted Earnings                
                Per Share) (Details)                                             
13: R75         Earnings Per Share (Schedule Of Number Of           HTML     31K 
                Anti-Dilutive Stock Options) (Details)                           
63: R76         Segment Reporting (Details)                         HTML     79K 
73: R77         Fair Value Measurements (Narrative) (Details)       HTML     32K 
43: R78         Fair Value Measurements (Schedule of Assets and     HTML     73K 
                Liabilities) (Details)                                           
16: R79         Hedging Instruments (Narrative) (Details)           HTML     63K 
46: R80         Hedging Instruments (Derivatives Designated In      HTML     37K 
                Cash Flow Hedging Relationships) (Details)                       
15: R81         Hedging Instruments (Schedule Of Fair Values And    HTML     67K 
                Balance Sheet Classifications Of Derivatives                     
                Designated As Hedging Instruments) (Details)                     
93: XML         IDEA XML File -- Filing Summary                      XML    181K 
55: XML         XBRL Instance -- idxx2019q310-q_htm                  XML   2.90M 
31: EXCEL       IDEA Workbook of Financial Reports                  XLSX     97K 
 7: EX-101.CAL  XBRL Calculations -- idxx-20190930_cal               XML    264K 
 8: EX-101.DEF  XBRL Definitions -- idxx-20190930_def                XML    536K 
 9: EX-101.LAB  XBRL Labels -- idxx-20190930_lab                     XML   1.48M 
10: EX-101.PRE  XBRL Presentations -- idxx-20190930_pre              XML    918K 
 6: EX-101.SCH  XBRL Schema -- idxx-20190930                         XSD    158K 
78: JSON        XBRL Instance as JSON Data -- MetaLinks              355±   521K 
83: ZIP         XBRL Zipped Folder -- 0000874716-19-000036-xbrl      Zip    317K 


‘EX-32.1’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED BY
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         
In connection with the report on Form 10-Q of IDEXX Laboratories, Inc. (the “Company”) for the quarter ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that:


(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



President and Chief Executive Officer

 

 

A signed original of this written statement required by Section 906, has been provided to IDEXX Laboratories, Inc. and will be retained by IDEXX Laboratories, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.







Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:10/31/194,  8-K
For Period end:9/30/19
 List all Filings 
Top
Filing Submission 0000874716-19-000036   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 3:04:41.1pm ET